August 5, 2026

Conceptual illustration representing GLP-1 medication hair loss from Ozempic and Wegovy, showing delicate floating hair strands
HairLoss

GLP-1 Medication Hair Loss: Ozempic, Wegovy, and What the 2026 BMJ Study Reveals

A landmark July 2026 BMJ study of nearly 40,000 patients confirms GLP-1 medication hair loss is a clinically validated concern, with Ozempic and Wegovy users facing a 37% higher alopecia risk. Understanding whether you’re experiencing temporary telogen effluvium or permanent androgenetic alopecia is critical. This guide breaks down the mechanisms, your personal risk factors, and exactly when to seek treatment.

Scroll to Top